AGC Biologics signs deal to develop, manufacture enzymes for Flen Health's diabetic foot ulcer therapy

PUBT · 3d ago
AGC Biologics signs deal to develop, manufacture enzymes for Flen Health's diabetic foot ulcer therapy
  • AGC's biologics unit signed an agreement with Flen Health to develop and manufacture recombinant enzymes for a diabetic foot ulcer therapy.
  • The Heidelberg, Germany, site will produce lactoperoxidase and glucose oxidase at 100-liter and 1,000-liter scales under Good Manufacturing Practice standards.
  • The work will support Flen Health's planned US Investigational New Drug application and Phase II clinical trial.
  • The agreement expands a feasibility collaboration launched in July 2025 to process development, scale-up and manufacturing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.